Rare Causes of Acute Coronary Syndrome: The JAK2 V617F Mutation-Positive Myeloproliferative Neoplasms: A Cardio-Hematological Perspective

Silvia Cantoni; Claudia Colombo; Francesco Soriano; Jacopo Andrea Oreglia; Alice Sacco; Silvio Veronese; Dario Brunelli; Andrea Rubboli; Nuccia Morici

doi:10.1055/a-1742-0361

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2022; 122(08): 1429-1431
DOI: 10.1055/a-1742-0361

Letter to the Editor

Rare Causes of Acute Coronary Syndrome: The JAK2 V617F Mutation-Positive Myeloproliferative Neoplasms: A Cardio-Hematological Perspective

Autor*innen

Silvia Cantoni

¹Division of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Claudia Colombo

²Intensive Coronary Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Francesco Soriano

³Division of Interventional Cardiology, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Jacopo Andrea Oreglia

³Division of Interventional Cardiology, De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Alice Sacco

²Intensive Coronary Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Silvio Veronese

⁴Division of Pathological Anatomy, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Dario Brunelli

²Intensive Coronary Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
Andrea Rubboli

⁵Division of Cardiology, Department of Cardiovascular Diseases, AUSL Romagna, Ospedale S. Maria delle Croci, Ravenna, Italy
Nuccia Morici

²Intensive Coronary Care Unit and De Gasperis Cardio Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy

Abstract

Volltext

Referenzen

References
1 Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017; 92 (01) 94-108
2 Barbui T, Falanga A. Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thromb Res 2016; 140 (Suppl. 01) S71-S75
3 Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019; 3 (11) 1729-1737
4 Guadall A, Lesteven E, Letort G. et al. Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features. Thromb Haemost 2018; 118 (09) 1586-1599
5 Enblom A, Lindskog E, Hasselbalch H. et al. High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med 2015; 26 (05) 344-347
6 Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 2013; 160 (01) 70-79
7 Xiong N, Gao W, Pan J, Luo X, Shi H, Li J. Essential thrombocythemia presenting as acute coronary syndrome: case reports and literature review. J Thromb Thrombolysis 2017; 44 (01) 57-62
8 Leonardi S, Gragnano F, Carrara G. et al. Prognostic implications of declining hemoglobin content in patients hospitalized with acute coronary syndromes. J Am Coll Cardiol 2021; 77 (04) 375-388